A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.
Clinical trial NCT03016013 · COMPLETED
Trial details
- NCT number
- NCT03016013
- Sponsor
- RemeGen Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-03-29
- Primary completion
- 2022-11-19
- Enrollment
- 479
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.